GenSpera preparing anti-cancer drug compound for Phase II study

SAN ANTONIO BUSINESS JOURNAL

http://www.bizjournals.com/sanantonio/news/2012/03/29/genspera-preparing-anti-cancer-drug.html

GenSpera preparing anti-cancer drug compound for Phase II study

San Antonio Business Journal by James Aldridge,

Date: Thursday, March 29, 2012, 10:14am CDT

GenSpera Inc. has completed the dose-escalation component of the company’s Phase I trial of its lead chemotherapeutic agent, G-202.

The trial will continue in up to 18 additional patients in order to further refine the dosing regimen and determine a recommended dose for Phase II clinical studies. The Phase I trial currently is being conducted at the University of Wisconsin Carbone Cancer Center in Madison; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore and the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio    The University of Texas Health Science Center at San Antonio Latest from The Business Journals Follow this company in San Antonio.

San Antonio-based GenSpera (OTCBB: GNSZ) is a development stage oncology company. GenSpera is working to perfect a technology platform that has the ability to deliver thapsigargin, a plant-derived cytotoxin, only within the tumor. The company’s platform is based on nine U.S. patents.

For more information, visit this link.

One Reply to “GenSpera preparing anti-cancer drug compound for Phase II study”

  1. Local business press coverage counts. For a lot. This piece about GenSpera’s continuing clinical trial helps raise the company’s profile among investors, potential partners and in the San Antonio biotech community, which is gaining a national reputation.

Leave a Reply

Your email address will not be published. Required fields are marked *